Considering the well-documented role of GSK3β in cancer progression and resistance to therapy, our findings indicate that IL-24-based treatments might provide a novel approach to targeting prostate cancer cells while reducing effects on normal tissues. This evidence concerns the gene GSK3B and Familial prostate cancer.